Previous 10 | Next 10 |
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results...
2024-05-22 05:07:36 ET More on AngioDynamics AngioDynamics: A Story To Monitor A Leaner AngioDynamics Is A High-Risk Execution-Driven Story AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript AngioDynamics upgraded at Oppenheimer on pipeline progress ...
Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer tr...
2024-05-19 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-14 14:27:46 ET Summary AngioDynamics, Inc. is struggling for profitability and its stock hit an all-time low of $5.26 on March 25th, 2024. However, the company is undergoing a restructuring, eliminating its manufacturing capabilities and focusing on its profitable medical ...
2024-05-09 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
New data finds AlphaVac F18 85 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides significant improvement in right ventricular function and reduction in clot burden AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical tech...
2024-04-09 16:49:42 ET Summary AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonar...
2024-04-09 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-05 09:19:01 ET More on AngioDynamics AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics gets FDA clearance for pulmonary embolism treatment device AngioDynamics Q3 2024 Ear...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...